Angus Liu is a Deputy Editor at Fierce Pharma and Fierce Biotech. He focuses on various aspects of medicine and healthcare, including oncology, immunotherapy, and digital health, while also covering pharmaceutical regulation and healthcare administration. Angus's work has been featured in Biotech, NewsBreak, and Fierce Pharma.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Angus Liu's coverage predominantly focuses on the healthcare and pharmaceutical industry. His articles reflect a strong emphasis on drug development, FDA approvals, clinical trials, and specific medications within the pharmaceutical industry.
Given this focus, Angus would likely be receptive to pitches from experts who have in-depth knowledge of drug development processes or regulatory affairs in the pharmaceutical industry. Pitches offering insights into recent clinical trial outcomes or FDA announcements related to new drugs may also capture his interest.
Sources with access to relevant data or those involved in government announcements pertaining to healthcare regulation could also provide valuable perspectives for Angus's coverage. It is important for potential sources to offer fact-based analysis and credible commentary that aligns with the themes covered in Angus's articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angus Liu
With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. Akeso's CEO countered concerns over shrinking lung cancer data for ivonescimab as the PD-1xVEGF drug delivered its first phase 3 win outside lung cancer. A U.S. congressman says China is "beating us on our ground game" in biotech. And more.
By: Angus Liu
The FDA has approved Takeda’s Mimrylo (rusfertide) for polyc
By: Angus Liu
Jazz Pharmaceuticals has added a second overall survival win to Ziihera's cap, bolstering the bispecific's claim as the new HER2 agent of choice in stomach cancer.
By: Angus Liu
Novartis appears to have broken the curse of the BTK inhibitor class. The Swiss pharma announced Tuesday that two phase 3 trials for Rhapsido in relapsing multiple sclerosis hit their goals without any liver safety flags.
By: Angus Liu
As part of the “most favored nation” (MFN) drug pricing deal the Trump administration signed with obesity giants Eli Lilly and Novo Nordisk, Medicare recently launched a “bridge” model, offering we
Novartis could cut around 130 jobs in Switzerland as it rethinks its biologics technical development and production footprint in Basel.
By: Angus Liu
About two years ago, a head-to-head progression-free survival win made Akeso and Summit Therapeutics' ivonescimab—and the PD-1xVEGF class—the most promising agent to replace Keytruda as the new cancer immunotherapy king. Now, that same trial has met its overall survival endpoint, but to a far more measured reception.
By: Angus Liu
GSK, Roche and Novartis continued Big Pharma's dealmaking spree with Asian companies. Three midsized Asian biopharmas reached “most favored nation” deals with the White House.
By: Angus Liu
In a rare divergence from its own expert panel, the FDA has
By: Angus Liu
In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival win in first-line small cell lung cancer (SCLC).
